Welcome to our dedicated page for NexGel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on NexGel stock.
NexGel, Inc (symbol: NXGL) specializes in the manufacture of advanced hydrogel solutions. The company's core business revolves around creating unique trans-dermal delivery systems initially developed and FDA-approved for the hospital wound care market. Today, NexGel has expanded its offerings to include consumer over-the-counter (OTC) products, prescription (Rx) applications, medical devices, and cosmetic products.
NexGel Inc is renowned for its high water content, electron beam cross-linked, aqueous polymer hydrogels. These gels are integral to various applications such as wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company's expertise lies in producing custom gels utilizing proprietary manufacturing technologies. The hydrogels and consumer products are created through a combination of proprietary and non-proprietary mixing, coating, and cross-linking technologies.
The company's recent achievements and current projects highlight its ongoing commitment to innovation and excellence in the hydrogel market. NexGel continually explores new partnerships and collaborations to enhance its product offerings and market reach.
For investors and stakeholders, it is important to note the company's strategic communications are managed by KCSA, with Valter Pinto serving as the Managing Director. NexGel’s financial condition and market performance are presented through regular updates, ensuring transparency and keeping investors well-informed.
For the latest developments, financial updates, and detailed information about NexGel, Inc, please refer to the following contact details:
Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications
Phone: 212.896.1254
Email: valter@kcsa.com
NEXGEL (NASDAQ: NXGL, NXGLW) announced positive outcomes from its proof-of-concept study on diclofenac hydrogel patches, aimed at treating pain including arthritis and muscle aches. The study showed that NEXGEL's patches delivered pain relief faster and were longer-acting compared to the leading treatment. These patches adhered to the skin gently for 8-12 hours. CEO Adam Levy expressed optimism about the product's potential and plans for human clinical studies, while seeking strategic partnerships for future development.
NEXGEL (NASDAQ: NXGL, NXGLW) announced the development of a new proprietary hydrogel eye patch to treat amblyopia, commonly known as lazy eye. The patch, expected to be available in the first half of 2023, aims to provide a gentler alternative to traditional eye patches, which can irritate sensitive skin. Amblyopia affects approximately 2-4% of the U.S. population and the global treatment market is projected to exceed $6 billion by 2027. This innovation highlights NEXGEL's commitment to enhancing pediatric care while meeting a growing market demand.
NEXGEL, a provider of high-water-content hydrogel products, announced CEO Adam Levy's participation in two upcoming conferences: the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida, and the LD Micro Main Event XV from October 25-27, 2022, in Los Angeles, California. Levy will speak at the LD Micro conference on October 26 at 8:30 AM PT. Interested investors can schedule 1x1 meetings through their respective representatives.
NEXGEL has announced promising results from a study published in SAGE Journals regarding its SilverSeal hydrogel dressing. The study involved 40 foot and ankle patients and evaluated post-surgical scarring and complications. Results showed that patients using SilverSeal experienced significant improvements in scar quality, reduced pain, and lower itching at the surgical site compared to those with a standard petroleum-based dressing. No postoperative complications were reported in either group, suggesting SilverSeal's potential in enhancing surgical recovery.
NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board. Dr. Nelson is a pediatric ophthalmology leader with extensive credentials, including roles at Wills Eye Hospital and Thomas Jefferson University. Dr. Chesen is a seasoned ophthalmologist with over 33 years of experience. Their addition aims to enhance NEXGEL's development of high-water-content hydrogel products for healthcare applications. CEO Adam Levy emphasized that their expertise will significantly aid in advancing the company's innovative hydrogel solutions.
NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) announced that CEO Adam Levy will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022. The presentation is scheduled for September 14, from 9:00 A.M. to 9:30 A.M. Eastern Time. Interested investors can contact their H.C. Wainwright representative or email NEXGEL@kcsa.com for 1x1 meetings. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications, having over two decades of experience in developing these innovative solutions.
NEXGEL reported a 35% year-over-year revenue growth to $561 thousand for Q2 2022, showing a 42% sequential increase. The rise is attributed to successful launches and demand for branded products, such as MEDAGEL Pro Pads. Gross profit improved to $101 thousand, with an 18% margin. However, operating expenses rose to $819 thousand, driven by increased R&D investments and higher SG&A costs. As of June 30, 2022, cash and equivalents stood at $9.7 million, ensuring a solid financial position for ongoing growth initiatives.
NEXGEL (NASDAQ: NXGL) will report its financial and operating results for Q2 2022 on August 10, 2022, after market close. Following the release, a conference call will be held at 4:30 P.M. ET the same day. Interested individuals can join the call via a U.S. toll-free number or international dial-in options, and a webcast will be available on the company’s Investor Relations website. A replay of the call will be accessible until August 17, 2022. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications.
NEXGEL (NASDAQ: NXGL, NXGLW) has launched the MEDAGEL Hydroliner Pro pads designed to protect eyelashes during cosmetic services like extensions and lifts. These pads offer a breathable, flexible, and skin-friendly alternative to traditional options, preventing slippage while being gentle on sensitive skin. They aim to enhance client comfort, allowing for easy removal and replacement during the application process. This product marks NEXGEL's first proprietary business-to-business offering, expanding its innovative hydrogel product line.
NEXGEL (NASDAQ: NXGL, NXGLW) has launched a partnership with Partners for World Health to provide humanitarian support in Ukraine. For every two boxes of SilverSeal® purchased, one will be donated to those in need. In June, 458 boxes were donated, equating to 1,832 healing patches. CEO Adam Levy emphasized the importance of treating skin injuries in crisis zones. The initiative addresses urgent medical needs amid ongoing conflict, aiming to deliver essential supplies through various shipping methods.